ImmunoCellular Therapeutics, Ltd. announced consolidated earnings results for the fourth quarter and full year ended December 31, 2017. For the quarter, the company reported net loss for the quarter ended December 31, 2017, was $431,000, or $0.01 per basic and diluted common share, compared to $6.3 million, or $1.36 per basic and diluted common share, for the quarter ended December 31, 2016. The decrease in the net loss is attributable to reduction in research and development associated with the suspension of the phase 3 trial of ICT-107 as well as certain discounts that the Company negotiated with key vendors. For the year, the company reported loss before other income was $21,153,444 compared with $24,112,125 a year ago. Net loss before provision for income taxes was $14,312,007 compared with $22,085,702 a year ago. Net loss attributable to common shareholders was $17,681,653 compared with $22,085,702 a year ago. Net loss attributable per share to common stockholder, basic and diluted was $1.23 compared with $7.89 a year ago. The 2017 net loss available to common stockholders includes the net loss of $14.3 million, plus $2.3 million of deemed dividends and $1.0 million of original issue discount associated with the convertible preferred stock issued as part of the July 2017 financing. There were no similar charges during 2016.